Chemokine receptor 5 blockade modulates macrophage trafficking in renal ischaemic-reperfusion injury

Kyung Don Yoo1 | Ran-hui Cha2 | Sunhwa Lee3,4 | Ji Eun Kim5 | Kyu Hong Kim4 | Jong Soo Lee1 | Dong Ki Kim6,7,8 | Yon Su Kim4,6,7,8,9 | Seung Hee Yang8,9

1Department of Internal Medicine, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan, Korea
2Department of Internal Medicine, National Medical Center, Seoul, Korea
3Department of Internal Medicine, Kangwon National University Hospital, Chuncheon, Korea
4Department of Biomedical Sciences, College of Medicine, Seoul National University, Seoul, Korea
5Department of Internal Medicine, Korea University Guro Hospital, Seoul, Korea
6Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea
7Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea
8Kidney Research Institute, Seoul National University, Seoul, Korea
9Biomedical Research Institute, Seoul National University Hospital, Seoul, Korea

Correspondence
Seung Hee Yang, Kidney Research Institute, Seoul National University, Seoul, Korea
and Biomedical Research Institute, Seoul National University Hospital, 101 Daehakro, Chongno-gu, Seoul 03080, Korea.
Email: ysh5794@gmail.com

Funding information
Korea Healthcare Technology R&D Project, Ministry of Health and Welfare, Republic of Korea Grant, Grant/Award Number: HI11C0631; Young Investigator Research Grant from the Korean Society of Nephrology, Grant/Award Number: KSN 2017

Abstract
Chemokine receptor 5 (CCR5) is a pivotal regulator of macrophage trafficking in the kidneys in response to an inflammatory cascade. We investigated the role of CCR5 in experimental ischaemic-reperfusion injury (IRI) pathogenesis. To establish IRI, we clamped the bilateral renal artery pedicle for 30 min and then reperfused the kidney. We performed adoptive transfer of lipopolysaccharide (LPS)-treated RAW 264.7 macrophages following macrophage depletion in mice. B6.CCR5−/- mice showed less severe IRI based on tubular epithelial cell apoptosis than did wild-type mice. CXCR3 expression in CD11b+ cells and inducible nitric oxide synthase levels were attenuated in B6.CCR5−/- mice. B6.CCR5−/- mice showed increased arginase-1 and CD206 expression. Macrophage-depleted wild-type mice showed more injury than B6.CCR5−/- mice after M1 macrophage transfer. Adoptive transfer of LPS-treated RAW 264.7 macrophages reversed the protection against IRI in wild-type, but not B6.CCR5−/- mice. Upon knocking out CCR5 in macrophages, migration of bone marrow-derived macrophages from wild-type mice towards primary tubular epithelial cells with recombinant CCR5 increased. Phospho-CCR5 expression in renal tissues of patients with acute tubular necrosis was increased, showing a positive correlation with tubular inflammation. In conclusion, CCR5 deficiency favours M2 macrophage activation, and blocking CCR5 might aid in treating acute kidney injury.

KEYWORDS
acute kidney injury, bilateral ischaemia-reperfusion injury, CC chemokine receptor 5, chemokine, macrophage
1 | INTRODUCTION

Renal ischaemia-reperfusion injury (IRI) is a complicated orchestrated event that elicits diverse immunological responses. Monocytes/macrophages, which exhibit great pliability, are important components of renal IRI. Their presence in the kidneys is closely correlated with a loss of renal function, and plasticity of macrophages affects the incidence of acute renal damage owing to chronic fibrosis.

Chemokine receptor 5 (CCR5) is a G protein-coupled receptor that spans seven transmembrane domains and a co-receptor for macrophage-trophic human immunodeficiency virus (HIV) type 1 strains. CCR5 is mainly associated with organ development, including angiogenesis, haematopoiesis, metastasis and chemotaxis. It is encoded on chromosome 3p21 and expressed by various immune cells such as resting T lymphocytes that have memory and effector T-cell phenotypes, monocytes, macrophages and immature dendritic cells. Several ligands, including RANTES (regulated on activation, normal T cell expressed and secreted/CCL5), monocyte chemo-attractant protein 1 (MCP-1), macrophage inflammatory protein (MIP)-1α and MIP-1β, react with CCR5, are activated by CCR5 retroactive to CCR5 ligands.

CCR5 signalling plays various roles in inflammation and chemokine receptor expression because of macrophage heterogeneity. A distinction between M1 and M2 macrophages suggests that the initiation and response to lipopolysaccharide (LPS)- or IFN-γ-induced stimulation are dependent on different signalling pathways of the Th1 or Th2 response. M2 macrophages are quite different from classically activated macrophages that produce trophic amines. Phenotypic diversity of macrophages is important in acute ischaemic kidney injury development and progression to chronic kidney disease. Interestingly, several cytokines and chemokines are involved in the differentiation, recruitment and migration of monocytes and macrophages during this process. CCR2 and MCP-1 play key roles in macrophage heterogenicity and plasticity, but insufficient data are available on the association between CCR5 and the origin and subsets of macrophages. Moreover, data from post-transplantation biopsies show conflicting results because M2 macrophage deposition occurs during pro-inflammatory reactions rather than during tissue repair, indicating that further research is necessary.

Here, we aimed to determine (a) the effect of macrophage phenotype on the expression of CCR5 and other chemokines, (b) the influence of macrophage phenotype on CCR5 signalling inhibition, and (c) the relevance of the CCR5 signalling pathway to IRI using in vivo and in vitro models. Finally, we analysed post-transplantation kidney biopsies to clarify the association between CCR5 and macrophages in acute kidney injury and clinical outcomes.

2 | MATERIALS AND METHODS

All experiments were performed with the approval of the Institutional Animal Care and Use Committee of the Clinical Research Institute of Seoul National University Hospital and in accordance with the Guidelines for the Care and Use of Laboratory Animals of the National Research Council. All experiments dealing with human specimens were also approved by the institutional review board of our institution (IRB number: H1910-011-1067). The experimental methods used in our study have been previously described. All experiments were conducted in accordance with the guidelines of the 2013 Declaration of Helsinki.

2.1 | Experimental animals

Male, 8-week-old, C57BL/6 (B6) mice were purchased from Orient Company. B6.CCR5−/− mice were originally produced by the Jackson Laboratory. All mice were raised in a pathogen-free animal facility. For extended methods related to in vitro and in vivo manipulations, including induction of renal ischaemic-reperfusion injury (IRI), histologic analysis, confocal microscopy, quantitative real-time PCR, Western blot, cytokine assay, flow cytometry, mouse tubular epithelial cell and bone marrow-derived cell isolation, culture, in vitro cell migration assay, and statistical methods, as well as the functional study protocol and ischaemia-induced hypoxic condition procedures, please refer to online supplemental data.

3 | RESULTS

3.1 | Depletion of CCR5 attenuates ischaemia-reperfusion injury

To determine the specific role of CCR5 in IRI in the kidney, we induced renal ischaemia in mice. Renal function deteriorated significantly after IRI in the sham control and wild-type disease control mice (Cr 0.46 ± 0.03 mg/dL vs 2.05 ± 0.05 mg/dL; ***P < .001). In B6.CCR5-deficient (B6.CCR5−/−) mice, however, the severity of renal dysfunction was less than that in wild-type B6 mice (Cr 2.05 ± 0.05 mg/dL vs 1.59 ± 0.07 mg/dL; **P < .01) (Figure 1A). This pattern was also observed in the level of blood urea nitrogen (BUN) (BUN 170.8 ± 7.70 mg/dL vs 117.6 ± 10.85 mg/dL; *P < .05).

IRI-induced tubular necrosis involves the disruption of tubular epithelial cells. The damage was more extensive in wild-type than in B6.CCR5−/− mice (Figure 1B), and the number of CD3− (Figure 1C), F4/80− (Figure 1D), MPO− (Figure 1E), caspase-3− (Figure 1F), and TUNEL− (Figure 1G) positive cells was much lower in B6.CCR5−/− than in wild-type mice. These histological changes were consistent with the functional data.

3.2 | Effects of CCR5 deficiency and changes in cytokine milieu

To examine how patterns of cytokine expression affect the extent of renal damage caused by IRI, we quantified mRNA levels using real-time PCR 24 hours after induction of IRI. Pro-inflammatory cytokines
and chemokines such as interferon-γ (IFN-γ), IL-12 and CCR5 were increased by IRI in wild-type mice. However, in B6.CCR5<sup>−/−</sup> mice, pro-inflammatory cytokines were significantly suppressed. Although IRI induced an increase in pro-inflammatory cytokines in wild-type mice, B6.CCR5<sup>−/−</sup> mice showed enhanced expression of regulatory cytokines (IL-10) during IRI (Figure 2A). Enzyme-linked immunosorbent assay (ELISA), performed on whole kidney protein extracts, showed that IL-4, IL-10 and IL-13, but not IFN-γ, were increased in response to IRI in CCR5<sup>−/−</sup> mice (Figure 2B).

### 3.3 Decreased T-cell infiltration in B6.CCR5<sup>−/−</sup> compared to that in wild-type mice

Fluorescence-activated cell sorting (FACS) staining of intrarenal lymphocytes for CCR5 expression showed that trafficking increased significantly in wild-type mice relative to that in the sham mice and isotype controls (34.44 ± 2.25% vs 6.19 ± 0.47%, ***<i>P</i> < .001) (Figure 3A). In sham mice, IFN-γ was expressed in 0.80% of the intrarenal CD4 T cells; furthermore, IRI induced an increase in intrarenal IFN-γ in wild-type mice, but attenuated this cytokine in B6.CCR5<sup>−/−</sup> mice (6.79 ± 0.82% vs 3.65 ± 0.21) (Figure 3B) (n = 3 for each animal group).

### 3.4 Macrophage and CCR5 crosstalk

B6.CCR5<sup>−/−</sup> mice showed less aggravated IRI in terms of apoptosis of tubular epithelial cells and creatinine (Cr) concentrations than did B6 wild-type mice. T-cell and macrophage infiltration decreased in B6.CCR5<sup>−/−</sup> compared with that in wild-type mice. Next, we assessed whether monocytes and macrophages migrated to the inflammation site and were induced by IRI. After IRI, CD11b<sup>+</sup>CCR5<sup>+</sup> cells were commonly expressed in wild-type mice and could be...
CXCR3 and CXCR4 are co-receptors of CCR5. Upon injury, CD11b+CXCR3+ cells were attenuated in B6.CCR5−/− compared with that in wild-type mice (Figure 4B). This pattern was similar to that in CD11b+CXCR4+ cells (Figure 4C). In this IRI model, CXCR3 infiltration was more prominent than CXCR4 infiltration upon confocal microscopy examination.

3.5 | CCR5 modulation of macrophage phenotype

Classical activation of M1 macrophages caused enzymes such as inducible nitric oxide synthase (iNOS), which produces nitric oxide from arginine, to be attenuated in B6.CCR5−/− compared with that in wild-type mice (Figure 5A). Arginase-1 is a marker of M2 macrophages.
that metabolizes l-arginine through a non-fungicidal pathway and is involved in tissue repair during an inflammation cascade. Using immunofluorescence, arginase-1 stained more intensely in B6.CCR5−/− than in wild-type mice (Figure 5B). The intrarenal mRNA expression of pro-inflammatory cytokines such as TNF-α, IFN-γ and MCP-1 decreased, whereas arginase-1 expression increased after IRI in B6.CCR5−/− mice (Figure 5C). CCR5 protein levels increased in wild-type mice after induction of IRI (Figure 5D). The M2 macrophage phenotype markers, arginase-1 and CD206, both increased in B6.CCR5−/− compared with that in wild-type mice (Figure 5E). Moreover, with CCR5 deficiency, there was a noteworthy increase in CD206+ macrophages (Figure 5F). CD206+CD11b+F4/80+ cells were induced in both wild-type and CCR5 knockout mice after IRI. The proportions of intrarenal CD206+ macrophages in each group were as follows: 1.09 ± 0.09% in control mice, 1.62 ± 0.40% in wild-type mice and 12.39 ± 1.43% in B6.CCR5−/− mice (Figure 5G).
To demonstrate further the role of CCR5 inhibition in hypoxia, we conducted in vitro experiments using tubular epithelial cell lines. We confirmed the expression of CCR5, and not HIF-1α or phospho(p)-CCR5, in normoxic conditions in human kidney-2 (HK-2) cells (Figure 6A). Simultaneously, we cultured HK-2 cells in hypoxic conditions with TAK779. Six hours after hypoxic injury, p-CCR5 was expressed. A CCR5-CXCR3 inhibitor attenuated these changes in expression in a dose-dependent manner (Figure 6A). Supernatant protein was quantified using ELISA to measure IL-6 and IL-8 levels (Figure 6B). Hypoxia increased IL-6 and IL-8 protein levels, and TAK779 attenuated this increase in a dose-dependent manner.

**FIGURE 5** The expression of macrophage heterogeneity in injured B6.CCR5−/− mice. A, The classical activation of M1 macrophages was representative of enzyme activity after inducing IRI; immunohistochemistry stain for iNOS was increased in wild-type mice. B, The immunohistochemistry stain for arginase-1 was intensified in B6.CCR5−/− mice compared to that in B6 WT mice. C, The results of real-time PCR revealed that the mRNA levels of Th1 inflammatory cytokines such as MCP-1 and iNOS were significantly decreased in B6.CCR5−/− mice compared to those in wild-type mice (**P < .01, n = 8 for each group). D, The protein levels of CCR5 were increased in wild-type mice after inducing IRI. E, In Western blot densitometry analyses, the expressions of M2 macrophage markers, such as CD206 and arginase-1, were substantially elevated in B6.CCR5−/− mice and attenuated in wild-type mice. F, The comparison of expression for CD206 immunofluorescence staining on confocal microscopic examination. G, Representative flow cytometry images for CD206+CCR5+ in CD11b+F4/80+ cells. The induction of CD206+ in CD11b+F4/80+ cells was increased in KO mice compared with that in wild-type mice. (**P < .01, n = 3 for each group).

### 3.6 CCR5 inhibition and amelioration of hypoxia-induced injury

To demonstrate further the role of CCR5 inhibition in hypoxia, we conducted in vitro experiments using tubular epithelial cell lines. We confirmed the expression of CCR5, and not HIF-1α or phospho(p)-CCR5, in normoxic conditions in human kidney-2 (HK-2) cells (Figure 6A). Simultaneously, we cultured HK-2 cells in hypoxic conditions with TAK779. Six hours after hypoxic injury, p-CCR5 was expressed. A CCR5-CXCR3 inhibitor attenuated these changes in expression in a dose-dependent manner (Figure 6A). Supernatant protein was quantified using ELISA to measure IL-6 and IL-8 levels (Figure 6B). Hypoxia increased IL-6 and IL-8 protein levels, and TAK779 attenuated this increase in a dose-dependent manner.
To investigate further the role of macrophage- and CCR5-signalling in IRI, LPS-treated RAW 264.7 macrophages were adoptively transferred into mice. RAW 264.7 macrophages were cultured with or without LPS (100 ng/mL) for 16 hours. B6 wild-type and B6.CCR5−/− mice were treated with liposomal clodronate (LC) (100 μL/10 g, intravenous) to deplete macrophages for 6 days to induce IRI (Figure 7A). ELISA of supernatants showed that IFN-γ protein (RAW 264.7 macrophages with LPS 177.2 ± 44.38 pg/mL, without LPS 46.55 ± 4.40 pg/mL; *P < .05) and iNOS mRNA (RAW 264.7 macrophages with LPS 5.76 ± 0.58 pg/mL, without LPS 1.03 ± 0.10 pg/mL; **P < .01) expression increased in LPS-treated RAW 264.7 macrophages, which tended to induce M1 macrophages (Figure 7B).

As expected, in both wild-type and B6.CCR5−/− mice, LC macrophage depletion showed a protective effect without the adoptive transfer of RAW 264.7 macrophages post-IRI induction (B6, Cr 3.02 ± 0.04 mg/dL vs B6 + RAW 264.7 macrophages + LC, Cr 2.02 ± 0.11 mg/dL; B6.CCR5−/−, Cr 2.57 ± 0.40 mg/dL vs B6.CCR5−/− + RAW 264.7 macrophages + LC, Cr 1.32 ± 0.19 mg/dL) (Figure 7C).

Finally, B6.CCR5−/− mice showed less severe injuries than wild-type mice after the transfer of RAW 264.7 macrophages, regardless of LPS pre-treatment without macrophage depletion (B6 + RAW 264.7 macrophages, Cr 3.02 ± 0.13 mg/dL vs B6.CCR5−/− + RAW 264.7 macrophages, Cr 2.25 ± 0.20 mg/dL).
Macrophages + LPS, Cr 3.56 ± 0.28 mg/dL vs B6.CCR5−/− + RAW 264.7 macrophages + LPS, Cr 2.56 ± 0.43 mg/dL (Figure 7C).

Adoptive transfer of LPS-treated RAW 264.7 macrophages with constitutive expression of iNOS reversed functional protection against IRI in wild-type mice, but not in B6.CCR5−/− mice. Further, adoptive transfer of M1 macrophages decreased mRNA expression of pro-inflammatory cytokines such as MCP-1 and iNOS in B6.CCR5−/− mice (Figure 7C,D).

3.8 | CCR5 modulation of activated macrophage migration

FACS staining gated on intrarenal macrophages showed a significant increase in CD11b+F4/80+ cells in wild-type compared with that in B6.CCR5−/− mice (95.3 ± 2.47% vs 82.6 ± 2.94%). (Figure 8A).

Moreover, in vitro macrophage migration assays were performed to clarify the effect of M1 macrophages on the chemotaxis of CCR5-deficient cells using a Boyden chamber with a filter membrane with 8-μm pores. The migration of BMDMs towards primary tubular epithelial cells with recombinant CCR5 was greater in wild-type mice by 25% than in B6.CCR5−/− mice. Additionally, blockade of CCR5 by TAK779 inhibited macrophage migration (Figure 8B). In a co-culture system of tubular epithelial cells and macrophages, macrophages induced iNOS mRNA expression (Figure 8C).

3.9 | Increased CCR5 expression in the kidney biopsy samples

The kidney biopsy tissues from kidney transplant recipients with delayed graft function were assessed for biopsy-proven acute tubular necrosis (ATN) without evidence of cellular or humoral rejection. Those with ATN were used to evaluate whether phosphorylation of CCR5 had a detrimental effect on IRI in patients undergoing transplantation. ATN in renal tissues from patients with glomerular
nephritis was also examined (Table 1). The characteristics of the 25 patients included in this analysis are shown in Table 1. We analysed p-CCR5 in renal biopsy samples from 14 patients who underwent transplantation (Table 1: case numbers 1-14), 11 patients with glomerulonephritis (Table 1: case numbers 15-25), and normal controls (Table 1: case numbers 26-31). Numbers of p-CCR5 cells increased relative to those in the normal control sample (Figure 9); in normal controls, p-CCR5 was scarcely detected. By immunohistochemical staining morphometry, kidney transplant recipients were more likely to have p-CCR5 cells than patients with glomerulonephritis (5.21 ± 1.32 vs 3.87 ± 1.71, *P* = .038). Renal tissue of patients with renal biopsy (n = 25) frequently contained p-CCR5 cells, and the number of these cells was positively correlated with tubule and vascular inflammation (tubulitis, *P* = .010, *r* = .508; intimal arteritis, *P* = .017, *r* = .474) (Table 1).

4 | DISCUSSION

In this study, B6.CCR5Δ32 mice experienced less severe renal IRI than did wild-type mice; comparatively, they had lower Cr concentrations, less tubular epithelial cell apoptosis, and less T-cell and macrophage infiltration. When vascular endothelial cells are injured by ischaemia/reperfusion, vascular permeability and adhesion molecule expression increase, and the accumulation of leucocytes in the kidney accelerates. The role of T lymphocytes in this process is well known20-23: when renal tubular cells are injured or stimulated in various ways, including activation by the complement system, expression of Toll-like receptors increases, promoting the production of chemokines such as MCP-1, CXCL8 and RANTES.24,25 We confirmed the results of previous studies regarding T cells and their relationship with IRI in a B6.CCR5Δ32 mouse model.26 Our results are consistent with a crucial role for T cells in the innate immune responses of both wild-type and B6.CCR5Δ32 mice. We presented for Figure S1 that is proposed mechanism of the association between CCR5, Th1-type T cells and monocyte/macrophage.20,25,26 Here, we focused on kidney damage and its up-regulation by CCR5, and explored the relevance and importance of macrophage infiltration.

Chemokines are 8-10 kD cytokines that stimulate leucocyte migration and chemotaxis to sites of inflammation. The chemokine receptor CCR5 is mediated by RANTES, monocyte inflammatory protein 1α (CCL3) and MIP-1β (CCL4), which are chemokine ligands produced in response to inflammation (Figure S2).7 Interestingly, in kidney transplant recipients with a CCR5-Δ32 base pair deletion, kidney graft survival is longer than that in recipients with wild-type CCR5, indicating the need for further studies to investigate the relationship between transplantation and CCR5 pathophysiology.27,28 CCR5 inhibition protects against kidney damage in several animal models of kidney disease, and CCR5 antagonists reduce kidney damage by lessening the deposition of mononuclear cells in an experimental glomerular nephritis model.29 CCR5 may attenuate renal damage by reducing T-cell deposition, as demonstrated in an acute kidney injury model.26 Based on animal models, when CXCR3 and its chemokine co-receptor CCR5 are both inhibited, acute and chronic rejection of heart transplants is reduced through decreased T-cell activity.30 Co-expression of CXCR3 and CCR5 is prominent in macrophages, as shown in previous HIV studies.7,31 Taken together, these results suggest that macrophages also play a crucial role in the action of chemokines that is likely similar to that of T cells.32 Therefore, in this study, we first observed crosstalk between CCR5...
| Case | Age*Sex | Primary disease of ESRD | Donor relation | Phosphorylation of CCR5 (%) | GS (%) | I | T | G | V | CT | CI | MM | AH | ESRD development |
|------|---------|-------------------------|----------------|-----------------------------|--------|---|---|---|---|----|----|-----|-----|-----------------|
| 1    | 63/M    | Unknown                 | DD             | 5.80 ± 1.90                 | 5.1    | 0 | 0 | 0 | 0 | 0  | 0  | 0   | 0   | YES             |
| 2    | 31/M    | HTN                     | DD             | 4.52 ± 1.23                 | 2.8    | 0 | 0 | 0 | 0 | 0  | 0  | 0   | 0   | NO              |
| 3    | 53/M    | GN                      | DD             | 5.74 ± 1.49                 | 7.4    | 0 | 0 | 0 | 1 | 0  | 0  | 0   | 1   | NO              |
| 4    | 65/M    | DM                      | DD             | 3.45 ± 0.57                 | 2.4    | 1 | 1 | 0 | 1 | 1  | 1  | 0   | 0   | NO              |
| 5    | 51/M    | DM                      | DD             | 3.76 ± 1.44                 | 49.2   | 1 | 1 | 0 | 0 | 1  | 1  | 0   | 0   | NO              |
| 6    | 55/M    | DM                      | DD             | 6.51 ± 1.57                 | 6.5    | 1 | 1 | 0 | 2 | 1  | 1  | 1   | 0   | 2   |
| 7    | 41/F    | DM                      | DD             | 7.53 ± 0.57                 | 19.0   | 1 | 0 | 0 | 1 | 0  | 0  | 0   | 0   | NO              |
| 8    | 69/F    | DM                      | DD             | 6.92 ± 1.06                 | 7.7    | 1 | 0 | 0 | 2 | 1  | 1  | 1   | 0   | NO              |
| 9    | 57/F    | DM                      | LD             | 6.31 ± 1.84                 | 33.3   | 1 | 0 | 0 | 0 | 0  | 0  | 0   | 0   | NO              |
| 10   | 67/M    | DM                      | DD             | 3.85 ± 1.17                 | -      | 0 | 0 | 0 | 0 | 0  | 0  | 0   | 0   | NO              |
| 11   | 37/F    | GN                      | DD             | 5.02 ± 2.18                 | 13.6   | 2 | 1 | 0 | 1 | 0  | 0  | 0   | 0   | NO              |
| 12   | 60/F    | PKD                     | DD             | 3.65 ± 1.12                 | 6.7    | 1 | 0 | 0 | 0 | 0  | 0  | 0   | 0   | YES             |
| 13   | 51/F    | DM                      | LD             | 5.51 ± 2.98                 | 3.6    | 1 | 0 | 0 | 0 | 0  | 0  | 0   | 0   | YES             |
| 14   | 39/F    | Unknown                 | DD             | 4.38 ± 1.93                 | -      | 0 | 0 | 0 | 0 | 0  | 0  | 0   | 0   | YES             |
| 15   | 64/M    | MCD                     |                 | 4.72 ± 1.50                 | 11.8   | 1 | 1 | 0 | 0 | 1  | 1  | 0   | 0   | NO              |
| 16   | 62/M    | MCD                     |                 | 5.41 ± 1.63                 | 14.3   | 1 | 1 | 0 | 0 | 0  | 0  | 0   | 0   | NO              |
| 17   | 62/M    | MCD                     |                 | 6.67 ± 2.06                 | 11.1   | 1 | 1 | 0 | 0 | 0  | 0  | 0   | 0   | NO              |
| 18   | 86/M    | MN                      |                 | 1.40 ± 1.93                 | 31.4   | 2 | 2 | 0 | 0 | 2  | 1  | 0   | 3   | YES             |
| 19   | 34/M    | MN                      |                 | 2.74 ± 1.10                 | 2.2    | 1 | 1 | 0 | 0 | 0  | 0  | 0   | 0   | NO              |
| 20   | 78/M    | IgAN                    |                 | 3.51 ± 1.86                 | 5.0    | 1 | 1 | 0 | 0 | 1  | 1  | 0   | 0   | YES             |
| 21   | 23/F    | IgAN                    |                 | 5.27 ± 1.11                 | 86.7   | 2 | 1 | 0 | 0 | 3  | 2  | 0   | 3   | YES             |
| 22   | 55/F    | amyloidosis              |                 | 2.12 ± 0.79                 | 4.9    | 1 | 1 | 0 | 0 | 1  | 1  | 0   | 1   | NO              |
| 23   | 51/F    | MCD                     |                 | 1.84 ± 1.42                 | 40.0   | 1 | 1 | 0 | 0 | 0  | 0  | 2   | 0   | YES             |
| 24   | 59/F    | IgAN                    |                 | 5.21 ± 2.69                 | 6.4    | 1 | 1 | 0 | 0 | 1  | 0  | 0   | 1   | NO              |
| 25   | 5/F     | Unknown                 |                 | 3.78 ± 1.02                 | 11.1   | 1 | 1 | 0 | 0 | 1  | 0  | 0   | 0   | NO              |
| 26   | 25/F    | Control                 |                 | <0.50                      | -      | 0 | 0 | 0 | 0 | 0  | 0  | 0   | 0   | NO              |
| 27   | 20/M    | Control                 |                 | <0.50                      | -      | 0 | 0 | 0 | 0 | 0  | 0  | 0   | 0   | NO              |
| 28   | 19/M    | Control                 |                 | <0.50                      | -      | 0 | 0 | 0 | 0 | 0  | 0  | 0   | 0   | NO              |
| 29   | 50/F    | Control                 |                 | <0.50                      | -      | 0 | 0 | 0 | 0 | 0  | 0  | 0   | 0   | NO              |
| 30   | 29/M    | Control                 |                 | <0.50                      | -      | 0 | 0 | 0 | 0 | 0  | 0  | 0   | 0   | NO              |
| 31   | 21/M    | Control                 |                 | <0.50                      | -      | 0 | 0 | 0 | 0 | 0  | 0  | 0   | 0   | NO              |

Note: Pathological finding grade: 0, mild; 1, moderate; 2, severe. Pathological finding description: GS, global sclerosis (%); I, interstitial inflammation; T, tubulitis; G, glomerulitis; V, intimal arteritis; CT, chronic tubular atrophy; CI, chronic interstitial fibrosis; MM, mesangial matrix expansion; AA, arteriolar hyalinosis.

Abbreviations: DD, deceased donor; DM, diabetes mellitus; ESRD, end-stage renal disease; F, female; GN, glomerular nephritis; HTN, hypertension; Ig AN, immunoglobulin A nephropathy; LD, living donor; M, male; MCD, minimal change disease; MN, membranous nephropathy; PKD, polycystic kidney disease; UPCR, urine protein-creatinine ratio.

*Age at the time of Bx. Continuous variables are represented by mean ± SD and categorical variables are shown as frequency (%).
and other chemokines such as CXCR3 or CXCR4 (Figure 4). After inducing IRI, CCR5 co-localized with CD11b positive cells, and consequently, the CXCR3 chemokine, which binds to macrophages or T lymphocytes, was expressed at a significantly lower level in B6.CCR5<sup>−/−</sup> mice; however, CD11<sup>+</sup>CXCR4<sup>+</sup> expression was not significantly modulated. The difference in expression was more pronounced for CXCR3, suggesting that co-signalling with CXCR3 may be important for CCR5 function.

Next, to investigate the functional role of macrophage phenotype and CCR5 in IRI (Figure S3.), we compared heterogenic macrophage infiltration in wild-type and B6.CCR5<sup>−/−</sup> mice (Figure 5). As expected, macrophages in B6.CCR5<sup>−/−</sup> mice, which had less injury, were highly expressed for the CD206<sup>+</sup>M2 phenotype after IRI induction. In this study, we also showed that macrophage depletion with LC may reduce ischaemic acute kidney injury (AKI) in the context of CCR5 deficiency. Adoptive transfer of RAW 264.7 macrophages, which constitutively express iNOS, reversed the functional protection against AKI in LC-treated wild-type and B6.CCR5<sup>−/−</sup> mice (Figure 7). With LC-induced macrophage depletion, adoptive transfer of M1 macrophages to B6.CCR5<sup>−/−</sup> mice resulted in a significant increase in injury compared with that in mice treated with RAW 264.7 macrophages, or with RAW 264.7 macrophages and LPS (M1-polarized). This suggests that M2 macrophages are expressed at higher levels in B6.CCR5<sup>−/−</sup> mice and that their expression is down-regulated by LC depletion, indicating that transferred M1 macrophages may promote an inflammatory response. Macrophages contribute to IRI and accelerate inflammation through various cytokines, mononuclear deposition and epithelial cell apoptosis. Macrophage depletion and repletion have been studied previously in IRI mouse and rat models, and macrophages also contribute to long-term fibrosis after IRI. In hypoxic kidney conditions, macrophages secrete pro-angiogenic growth factors and pro-inflammatory cytokines. Macrophages respond to hypoxia by increasing chemokine secretion, which accelerates the recruitment and chemotaxis of macrophages and exacerbates hypoxia of the microenvironment itself. This is thought to be the main mechanism that attenuates damage in B6.CCR5<sup>−/−</sup> mice.

When IRI occurs, immune cells are deposited and cytokine overproduction occurs because hypoxia is caused by a response to transcription factors that stimulate cytokines, including nuclear factor κB (NF-κB), heat shock factor protein 1 and HIF-1α. Chemokines are also a major stimulant of chemotaxis, particularly when guiding neutrophils and M1 macrophages to the site of inflammation. Chemokine receptor 2 (CCR2) promotes macrophage migration directly in IRI, but the effect of CCR5 on macrophage migration in IRI is not well understood. In this study, in vitro experiments were conducted to determine the relationship between the chemotactic effects of CCR5 and macrophages. Macrophages enhanced the secretion of pro-inflammatory cytokines in tubular epithelial cells (TECs). Moreover, blockade of CCR5 and TAK779 inhibited the migration of macrophages (Figure 8). In recombinant CCR5-treated proximal TECs, macrophage migration (Figure 8B) and iNOS expression increased (Figure 8C). These results show that co-signalling of CCR5 and CXCR3 plays a major role in macrophage recruitment and migration through M1 macrophage activation, as well as in the Th1 response. We found that injury is alleviated by TAK779, which blocks both CCR5 and CXCR3. Co-signalling of CXCR3 is important for the crosstalk between macrophages and CCR5, as shown in Figure 4. To further support these findings, we have provided the results for the supplement experiment for CCR5 regulation under T cell-depleted conditions (Figures S4-S9). Polarization of macrophages results in a switch in chemokine receptor expression, allowing macrophages to enter lymphatic vessels and to be actively drained to lymphoid tissues, which are the native T-cell areas. Naive T cells interact with differently polarized macrophages and are activated, and T helper 1 (Th1) or 2 (Th2) effectors migrate to the peripheral tissues. IL-12, which is a pro-inflammatory molecule produced mainly by antigen-presenting cells (APCs), plays a key role in this process. IL-12 mainly activates natural killer cells and induces the differentiation of naïve CD4<sup>+</sup> T lymphocytes to interferon-gamma (IFN-γ)-producing Th1 effectors in cell-mediated immune responses to inflammation, and the autocrine and paracrine effects of IFN-γ activate APC recruitment and T-cell activation. These supplementary experiments were conducted to explore which of the T cells and macrophages plays the major role in the association between CCR5 and kidney IRI. Based on the results presented in Figures S4-S9 and the main results, we have been suggested that both T cells and macrophages are important and influence each other and that CCR5 plays a pivotal role in IRI (Figure S3). Proposed mechanism of the association between CCR5 and macrophage polarization and M1/M2 transition). However, further experiments for the underlying mechanisms are needed, especially for the heterogeneity in macrophage expression via CD206 and arginase-1 under T cell-depleted conditions in CCR5 KO mice.

Previous studies have indicated a correlation between CCR5 expression on the surface of T cells and macrophages and cellular rejection in patients with biopsy-proven acute rejection. In this study, to evaluate tissue expression of p-CCR5 in IRI, we performed IHC.
staining and morphometric analysis in pathologically confirmed ATN, but only in tissues from 25 patients, including kidney transplant recipients with no evidence of rejection and patients with glomerulonephritis. There was no difference in the renal survival rate in these patients based on a Kaplan-Meier curve for the occurrence of end-stage renal disease in accordance with morphometry positivity area (%) based grouping (lower than the median value of p-CCR5 vs higher than the median value p-CCR5; data not shown). However, tissue p-CCR5-positive areas increased with the severity of tubulitis and intimal arteritis (Table 1). We confirmed that inflammatory cells, including those with the CCR5 receptor for chemokine ligands in tubulitis and endotheliitis, correspond to the distribution of appropriate ligands.

In summary, we identified the role of CCR5, which modulates inflammation and immunity, in macrophage induction of IRI. We showed that CCR5 blockade attenuated IRI via the macrophage heterogeneous signalling pathway, irrespective of the anti-inflammatory effects of T cells. Modulation of the CCR5 pathway could thus prove useful as a new therapy for ischaemic AKI.

ACKNOWLEDGEMENTS
This study was supported by the Young Investigator Research Grant from the Korean Society of Nephrology (KSN 2017) and by a grant from the Korea Healthcare Technology R&D Project, Ministry of Health and Welfare, Republic of Korea Grant (grant number: HI11C0631).

CONFLICT OF INTEREST
The authors confirm that there are no conflicts of interest.

AUTHOR CONTRIBUTIONS
KD Yoo, SH Yang and YS Kim conducted most experiments, analysed the results and wrote most of the manuscript. SH Yang and KD Yoo conducted the experiments on the role of CCR5 and macrophages in kidney IRI. S Lee, JE Kim, KH Kim and SH Yang conducted the experiments on CCR5 and macrophage heterogeneity. RH Cha, JS Lee, and DK Kim conceived the idea for the project and wrote the manuscript with KD Yoo and SH Yang.

DATA AVAILABILITY STATEMENT
The data that support the findings of this study are available from the corresponding author, SH Yang, upon reasonable request.

ORCID
Kyung Don Yoo https://orcid.org/0000-0001-6545-6517
Ran-hui Cha https://orcid.org/0000-0003-2783-2600
Ji Eun Kim https://orcid.org/0000-0003-3094-2229
Dong Ki Kim https://orcid.org/0000-0002-5195-7852
Yon Su Kim https://orcid.org/0000-0003-3091-2388
Seung Hee Yang https://orcid.org/0000-0002-8575-6610

REFERENCES
1. Rogers NM, Ferenbach DA, Isenberg JS, Thomson AW, Hughes J. Dendritic cells and macrophages in the kidney: a spectrum of good and evil. Nat Rev Nephrol. 2014;10:625-643.
2. Vinuesa E, Hotter G, Jung M, Herrero-Fresneda I, Torras J, Sola A. Macrophage involvement in the kidney repair phase after ischaemia/reperfusion injury. J Pathol. 2008;214:104-113.
3. Ricardo SD, van Goor H, Eddy AA. Macrophage diversity in renal injury and repair. J Clin Investig. 2008;118:3522-3530.
4. Lech M, Grobmary R, Ryu M, et al. Macrophage phenotype controls long-term AKI outcomes–kidney regeneration versus atrophy. J Am Soc Nephrol. JASN. 2014;25:292-304.
5. Kinsey GR. Macrophage dynamics in AKI to CKD progression. J Am Soc Nephrol. JASN. 2014;25:209-211.
6. Martinez FO, Gordon S. The M1 and M2 paradigm of macrophage activation: time for reassessment. F1000prime Rep. 2014;6:13.
7. Alkhatib G. The biology of CCR5 and CXCR4. Current opinion in HIV and AIDS. 2009;4:96-103.
8. Dehmel S, Wang S, Schmidt C, et al. Chemokine receptor CCR5 deficiency induces alternative macrophage activation and improves long-term renal allograft outcome. Eur J Immunol. 2010;40:267-278.
9. Mills CD, Kincaid K, Alt JM, Heilman MJ, Hill AM. M-1/M-2 Macrophages and the Th1/Th2 Paradigm. J Immunol. 2000;164:6166-6173.
10. Guiteras R, Flaquer M, Cruzado JM. Macrophage in chronic kidney disease. Clinical kidney journal. 2016;9:765-771.
11. Mantovani A, Sica A, Sozzani S, Allavena P, Vecchi A, Locati M. The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol. 2004;25:677-686.
12. Davis MJ, Tsang TM, Qiu Y, et al. Macrophage M1/M2 polarization dynamically adapts to changes in cytokine microenvironments in Cryptococcus neoformans infection. MBio. 2013;4:e00264-13.
13. Novak ML, Koh TJ. Phenotypic transitions of macrophages orchestrate tissue repair. Am J Pathol. 2013;183:1352-1363.
14. Toku D, Zhang W, Hor KL, et al. The role of macrophages in the development of human renal allograft fibrosis in the first year after transplantation. Am J Transplant. 2014;14:2126-2136.
15. Ikekuzmi Y, Suzuki T, Yamada T, et al. Alternatively activated macrophages in the pathogenesis of chronic kidney allograft injury. Pediatr Nephrol. 2015;30:1007-1017.
16. Yang SH, Lee JP, Jang HR, et al. Sulfatide-reactive natural killer T cells abrogate ischemia-reperfusion injury. J Am Soc Nephrol. 2011;22:1305-1314.
17. Lee JP, Yang SH, Lee HY, et al. Soluble epoxide hydrolase activity determines the severity of ischemia-reperfusion injury in kidney. PLoS ONE. 2012;7:e37075.
18. An JN, Yang SH, Kim YC, et al. Periostin induces kidney fibrosis after acute kidney injury via the p38 MAPK pathway. Am J Physiol Renal Physiol. 2019;316:F426-F437.
19. Lee JW, Bae E, Kwon SH, et al. Transcriptional modulation of the T helper 17 interleukin 17 axis ameliorates renal ischemia-reperfusion injury. Nephrol Dial Transplant. 2019;34:1481-1498.
20. Rabb H, Daniels F, O’Donnell M, et al. Pathophysiological role of T lymphocytes in renal ischemia-reperfusion injury in mice. Am J Physiol Renal Physiol. 2000;279:F525-F531.
21. De Greef KE, Ysebaert DK, Dauwe S, et al. Anti-B7-1 blocks mononuclear cell adherence in vasa recta after ischemia. Kidney Int. 2001;60:1415-1427.
22. Yokota N, Daniels F, Crosson J, Rabb H. Protective effect of T cell depletion in murine renal ischemia-reperfusion injury. Transplantation. 2002;74:759-763.
23. Han SJ, Lee HT. Mechanisms and therapeutic targets of ischemic acute kidney injury. Kidney Res Clin Pract. 2019;38:427-440.
24. Daha MR, van Kooten C. Is the proximal tubular cell a proinflammatory cell? Nephrol Dial Transplant. 2000;15:541-543.
25. Jang HR, Rabb H. Immune cells in experimental acute kidney injury. Nat Rev Nephrol. 2015;11:88-101.
26. Ko GJ, Linfert D, Jang HR, et al. Transcriptional analysis of infiltrating T cells in kidney ischemia-reperfusion injury reveals a pathophysiological role for CCR5. *Am J Physiol Renal Physiol*. 2012;302:F762-F773.
27. Fischereider M, Luckow B, Ho cher B, et al. CC chemokine receptor 5 and renal-transplant survival. *Lancet*. 2001;357:1758-1761.
28. Ran-hui Cha SHY, Kim HS, Kim SM, Park MH, Ha J, Kim YS. Genetic interactions between the donor and the recipient for susceptibility to acute rejection in kidney transplantation: polymorphisms of CCR5. *Nephrol Dial Transplant*. 2009;24:2919-2925.
29. Panzer U, Schneider A, Wilken J, Thompson DA, Kent SBH, Stahl RAK. The chemokine receptor antagonist AOP-RANTES reduces monocyte infiltration in experimental glomerulonephritis. *Kidney Int*. 1999;56:2107-2115.
30. Schnickel GT, Bastani S, Hsieh GR, et al. Combined CXCR3/CCR5 blockade attenuates acute and chronic rejection. *J Immunol*. 2008;180:4714-4721.
31. Moore JP, Doms RW. The entry of entry inhibitors: a fusion of science and medicine. *Proc Natl Acad Sci USA*. 2003;100:10598-10602.
32. Kakuta Y, Okumi M, Miyagawa S, et al. Blocking of CCR5 and CXCR3 suppresses the infiltration of macrophages in acute renal allograft rejection. *Transplantation*. 2012;93:24-31.
33. Paul Cockwell JW, Brooks CJ, Chakravorty SJ, Savage COS. Chemotraction of T cells expressing CCR5, CXCR3 and CX3CR1 by proximal tubular epithelial cell chemokines. *Nephrol Dial Transplant*. 2002;17(5):734-744.
34. Day YJ, Huang L, Ye H, Linden J, Okusa MD. Renal ischemia-reperfusion injury and adenosine 2A receptor-mediated tissue protection: role of macrophages. *Am J Physiol Renal Physiol*. 2005;288:F722-F731.
35. Jo SK, Sung SA, Cho WY, Go KJ, Kim HK. Macrophages contribute to the initiation of ischaemic acute renal failure in rats. *Nephrol Dial Transplant*. 2006;21:1231-1239.
36. Ko GJ, Boo CS, Jo SK, Cho WY, Kim HK. Macrophages contribute to the development of renal fibrosis following ischaemia/reperfusion-induced acute kidney injury. *Nephrol Dial Transplant*. 2008;23:842-852.
37. Tazzyman S, Murdoch C, Yeomans J, Harrison J, Muthana M. Macrophage-mediated response to hypoxia in disease. *Hypoxia* (Auckl). 2014;2:185-196.
38. Rahat MA, Bitterman H, Lahat N. Molecular mechanisms regulating macrophage response to hypoxia. *Front Immunol*. 2011;2:45.
39. Erwig LP. Macrophages and hypoxia in human chronic kidney disease. *Kidney Int*. 2008;74:405-406.
40. Takada M, Nadeau KC, Shaw GD, Marquette KA, Tilney NL, Tilney NL. The cytokine-adhesion molecule cascade in ischemia/reperfusion injury of the rat kidney. Inhibition by a soluble P-selectin ligand. *J Clin Invest*. 1997;99:2682-2690.
41. Anders HJ, Vielhauer V, Schlendorff D. Chemokines and chemokine receptors are involved in the resolution or progression of renal disease. *Kidney Int*. 2003;63:401-415.
42. Swaminathan S, Griffin MD. First responders: understanding monocyte-lineage traffic in the acutely injured kidney. *Kidney Int*. 2008;74:1509-1511.
43. Furui K, CCR2 signaling contributes to ischemia-reperfusion injury in kidney. *J Am Soc Nephrol*. 2003;14:2503-2515.
44. Ghosh R, Sharma A, Mitra DK, Agarwal SK, Dinda AK, Saxena A. Study of CC chemokine receptor 5 in renal allograft rejection. *Indian J Nephrol*. 2013;23:196-200.
45. Segerer S, Cui Y, Eitner F, et al. Expression of chemokines and chemokine receptors during human renal transplant rejection. *Am J Kidney Dis*. 2001;37:518-531.

**SUPPORTING INFORMATION**

Additional supporting information may be found online in the Supporting Information section.

*How to cite this article:* Yoo KD, Cha R-H, Lee S, et al. Chemokine receptor 5 blockade modulates macrophage trafficking in renal ischemia-reperfusion injury. *J Cell Mol Med*. 2020;24:5515–5527. [https://doi.org/10.1111/jcmm.15207](https://doi.org/10.1111/jcmm.15207)